HAYWARD, Calif., Dec. 12 /PRNewswire-FirstCall/ -- Cholestech Corporation today announced the appointment of Gregory L. Bennett as Vice President of Research and Development. Mr. Bennett has been Cholestech's Director of Engineering since November 2003, in charge of Process Engineering, Quality Control, Facilities, Product Transfer and Manufacturing Engineering. He brings over 14 years of technical leadership in medical device process development and product management to his new role.
Mr. Bennett succeeds Dr. Thomas Worthy who is retiring from Cholestech. Dr. Worthy has been Cholestech's Vice President of Development since August 1999 and was instrumental in the research, development and commercialization of Cholestech's Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and high sensitivity C-Reactive Protein (hs-CRP) tests. Prior to his current position, Dr. Worthy was Director of Technical Affairs.
Commenting on Dr. Worthy's retirement, Warren E. Pinckert II, Cholestech's President and Chief Executive Officer said, "Under Tom's leadership we have launched three new tests over the past 2 1/2 years, with a fourth scheduled soon. He leaves us with a good product pipeline for the future and all of us here at Cholestech wish Tom and his wife Pat all the best in the future."
Commenting on Mr. Bennett's appointment, Mr. Pinckert remarked, "During Greg's time at Cholestech, he has been instrumental in expanding our manufacturing capacity, reducing costs, and improving the LDX performance that led to our recent CRMLN Certification. We are very pleased to add Greg to our Executive Team and are confident his energy, experience and leadership skills will allow us to attain our new product revenue goals over the next several years."
Prior to joining Cholestech, Mr. Bennett was Director of Process Development Engineering for LifeScan Inc., a Johnson & Johnson company. In this position, he led a group responsible for the process development, scale-up and commercialization of several blood glucose monitoring devices. Before this position, Mr. Bennett held a variety of engineering leadership positions in both Operations and R&D at LifeScan, where he spent 12 years. Prior to LifeScan, Mr. Bennett held several engineering positions with Pechiney where he worked for seven years.
About Cholestech
Cholestech is committed to enabling people to lead longer, healthier and more active lives. Cholestech provides easy to use, accessible diagnostic tools and information to health care practitioners in over 35 countries around the world. Cholestech offers efficient and economic diagnostic testing for cholesterol and related lipids, blood glucose and glycemic control,high sensitivity C-Reactive Protein and liver function at the point of care. Health care providers can use the CLIA-waived Cholestech LDX(R) and GDX(TM) Systems to initiate and monitor the progress of patient therapy. By providing effective disease management solutions, Cholestech's goal is to be a leading provider of diagnostic tools and information for immediate risk assessment and therapeutic monitoring of heart disease and diabetes.
Cholestech LDX(R) is a registered trademark and Cholestech GDX(TM) is a trademark of Cholestech Corporation. All other trademarks mentioned in this document are the property of their respective owners. For more information about Cholestech and its products visit us on the web at www.cholestech.com.
Safe Harbor Statement of Cholestech Corporation Under the Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding: the timing of future product launches; Cholestech's future product pipeline; and Cholestech's ability to attain certain future goals. Actual results may differ materially from those in the forward-looking statements due to risks and uncertainties, including: risks inherent to the regulatory approval process; market acceptance and demand for Cholestech's current and future products; further regulatory changes and guidelines affecting the healthcare system in the United States; and risks inherent to future sales growth and the research and development process. Additional considerations and important risk factors are described in Cholestech's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.
Cholestech CorporationCONTACT: Warren E. Pinckert II, President and Chief Executive Officer ofCholestech Corporation, +1-510-732-7200, or wpinckert@cholestech.com; orinvestors, Jordan Goldstein of Financial Dynamics, +1-415-439-4520, orjgoldstein@fd-us.com, for Cholestech Corporation
Web site: http://www.cholestech.com/
